<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01709851</url>
  </required_header>
  <id_info>
    <org_study_id>GMD_05</org_study_id>
    <nct_id>NCT01709851</nct_id>
  </id_info>
  <brief_title>Performance Study to Test the GlucoMen®Day System Using Intravascular and Subcutaneous Microdialysis in Subjects With Type 1 Diabetes</brief_title>
  <official_title>A Single-center, Open, Pilot Trial to Investigate the Performance of the GlucoMen®Day System Using Intravascular and Subcutaneous Microdialysis in Subjects With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over the last years, a number of systems for continuous subcutaneous glucose monitoring have&#xD;
      been marketed and are routinely used in patients with diabetes to obtain more detailed&#xD;
      information about 24-hour glucose profiles.&#xD;
&#xD;
      In the hospital, numerous factors influencing glycemic control and possibly leading to&#xD;
      glucose excursions out of the desired range exist, e.g. interventions for which the patient&#xD;
      has to remain fasting or medications such as corticosteroids or vasopressors. A reliable&#xD;
      continuous glucose signal could help to observe levels of glycaemia not only at defined&#xD;
      time-points but continuously, making it possible for physicians and nursing staff to better&#xD;
      adjust antihyperglycemic therapy and to react before the patient is exposed to severe hypo-&#xD;
      or hyperglycaemia.&#xD;
&#xD;
      In the hospital setting, vascular access is granted in the majority of patients and could as&#xD;
      well be used as an alternative site for continuous glucose monitoring.&#xD;
&#xD;
      The aim of the present study is to assess accuracy of the glucose data obtained by means of&#xD;
      an intravascular microdialysis-based CGM system against venous blood glucose reference&#xD;
      measurements.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Point Accuracy of the microdialysis signal</measure>
    <time_frame>72 hours</time_frame>
    <description>MARD (mean absolute relative difference), MARE (mean absolute relative error), %Press analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate accuracy of the microdialysis signal</measure>
    <time_frame>72 hours</time_frame>
    <description>R-EGA (rate error grid analysis) and P-EGA (point error grid analysis)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">12</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Type 1 Diabetes - vMD and sMD</arm_group_label>
    <description>Patients will undergo vascular (vMD) and subcutaneous microdialysis (sMD) using the GMD-system (GlucoMen(R)Day-system)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 1 diabetes - vMD</arm_group_label>
    <description>Patients will undergo vascular microdialysis (vMD) using the GMD-system (GlucoMen(R)Day-system)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vascular microdialysis using the GMD-system</intervention_name>
    <description>Glucose levels will be monitored by means of vascular microdialysis using the GlucoMen(R)Day system</description>
    <arm_group_label>Type 1 diabetes - vMD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vascular and subcutaneous microdialysis using the GMD-system</intervention_name>
    <description>Glucose levels will be monitored by means of vascular and subcutaneous microdialysis using the GlucoMen(R)Day system</description>
    <arm_group_label>Type 1 Diabetes - vMD and sMD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with type 1 diabetes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained after being advised of the nature of the study&#xD;
&#xD;
          -  Male or female aged 18 - 75 years (both inclusive)&#xD;
&#xD;
          -  Type 1 diabetes treated with multiple daily insulin injection or continuous&#xD;
             subcutaneous insulin infusion for 12 months&#xD;
&#xD;
          -  Body mass index 20.0 - 29.5 kg/m² (both inclusive)&#xD;
&#xD;
          -  HbA1c &lt; 86.0mmol/mol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female of childbearing potential who is pregnant, breast-feeding or intend to become&#xD;
             pregnant or is not using adequate contraceptive methods.&#xD;
&#xD;
          -  Skin pathology or condition prohibiting needle insertion as judged by the&#xD;
             investigator.&#xD;
&#xD;
          -  History of bleeding disorder.&#xD;
&#xD;
          -  History of heparin-induced thrombocytopenia (HIT)&#xD;
&#xD;
          -  Current participation in another clinical study.&#xD;
&#xD;
          -  Significant acute or chronic illness that might interfere with subject safety or&#xD;
             integrity of results as judged by the investigator.&#xD;
&#xD;
          -  Lipodystrophy&#xD;
&#xD;
          -  Current treatment with systemic (oral or i.v.) corticosteroids or any anticoagulation&#xD;
             medication.&#xD;
&#xD;
          -  Blood donation or blood loss of more than 500 mL within 12 weeks prior to the study&#xD;
             day.&#xD;
&#xD;
          -  Known hypersensitivity to Fondaparinux sodium (Arixtra®).&#xD;
&#xD;
          -  Significant history of alcoholism or drug abuse or a positive result in urine&#xD;
             drug/alcohol screen.&#xD;
&#xD;
        Study day exclusion criteria:&#xD;
&#xD;
          -  Non-fasting (i.e. consumption of food or beverages, other than water, later than 22:00&#xD;
             hours the evening before the visit) except if slight intake of rapidly absorbable&#xD;
             carbohydrates has been necessary in order to prevent hypoglycaemia.&#xD;
&#xD;
          -  Positive result of alcohol breath test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas R. Pieber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz, Dept. of Internal Medicine, Endocrinology and Metabolism</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>October 11, 2012</study_first_submitted>
  <study_first_submitted_qc>October 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2012</study_first_posted>
  <last_update_submitted>April 15, 2013</last_update_submitted>
  <last_update_submitted_qc>April 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 diabetes</keyword>
  <keyword>Intravascular continuous glucose monitoring</keyword>
  <keyword>Subcutaneous continuous glucose monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

